We are live on
!
Find out more
VVM
Versant Venture Management Portfolio holdings
AUM
$141M
1-Year Est. Return
190.82%
This Fund
S&P 500
This Quarter
Est. Return
-4.53%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$513M
AUM Growth
-$450M
(-47%)
Cap. Flow
-$383M
Cap. Flow
% of AUM
-74.71%
Top 10 Holdings %
Top 10 Hldgs %
99.86%
Holding
13
New
1
Increased
1
Reduced
4
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Passage Bio
PASG
|
+$106M |
| 2 |
ADVM
Adverum Biotechnologies
ADVM
|
+$773K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$224M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$201M |
| 3 |
Ocular Therapeutix
OCUL
|
+$30.3M |
| 4 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
+$29M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$4.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CRISPR Therapeutics
CRSP
$4.68B
| $189M | 36.92% |
1,554,960
-1,485,502
| -49% | -$224M |
|
|
2
Passage Bio
PASG
$14.7M
| $86.7M | 16.89% |
+247,988
| New | +$106M |
|
3
Aligos Therapeutics
ALGS
$26.3M
| $74.9M | 14.59% |
131,694
| – | – |
|
|
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
| $50M | 9.74% |
506,823
+6,434
| +1% | +$773K |
|
|
GRTS
5
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $42M | 8.18% |
4,450,638
| – | – |
|
6
Crinetics Pharmaceuticals
CRNX
$8.88B
| $31M | 6.05% |
2,030,616
| – | – |
|
|
AKRO
7
DELISTED
Akero Therapeutics
AKRO
| $17.9M | 3.49% |
617,727
-160,000
| -21% | -$4.84M |
|
|
FLXN
8
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $11.7M | 2.28% |
1,310,169
-2,532,409
| -66% | -$29M |
|
9
Aprea Therapeutics
APRE
$7.6M
| $6.42M | 1.25% |
62,983
-8,333
| -12% | -$972K |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $2.47M | 0.48% |
543,753
| – | – |
|
|
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
| $715K | 0.14% |
101,855
| – | – |
|
|
12
Ocular Therapeutix
OCUL
$1.85B
| – | – |
-1,465,384
| Closed | -$30.3M |
|
|
NARI
13
DELISTED
Inari Medical, Inc. Common Stock
NARI
| – | – |
-2,298,217
| Closed | -$201M |
|
Similar funds
POIA
MAM
TM
IA
KCM
RB
YEPX
CFGW
Versant Venture Management's Q1 2021 Portfolio in Review
As of Q1 2021, Versant Venture Management held 13 positions worth $513M, down 47% from $963M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Versant Venture Management withdrew a net $383M in Q1 2021, closing 2 positions and reducing 4 holdings. Its most notable exit was Inari Medical, Inc. Common Stock, an estimated $201M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Versant Venture Management opened a new position in Passage Bio worth $86.7M.
- Versant Venture Management's largest Q1 2021 buy was Passage Bio: 247,988 shares worth $86.7M.
- Versant Venture Management added most to Adverum Biotechnologies in Q1 2021, an estimated $773K increase.
- Versant Venture Management's biggest Q1 2021 reduction was CRISPR Therapeutics, cutting an estimated $224M.
- Versant Venture Management fully exited Inari Medical, Inc. Common Stock in Q1 2021, selling an estimated $201M.
- Versant Venture Management's ten largest holdings make up 100% of its $513M portfolio in Q1 2021.
- Versant Venture Management opened 1 new position and closed 2 in Q1 2021.
- Versant Venture Management's portfolio value fell 47% quarter-over-quarter to $513M.
Based on Versant Venture Management's 13F filing for Q1 2021, filed 7 May 2021.